BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

385 related articles for article (PubMed ID: 11391579)

  • 1. Combined etoposide, ifosfamide, and cisplatin in the treatment of patients with advanced thymoma and thymic carcinoma: an intergroup trial.
    Loehrer PJ; Jiroutek M; Aisner S; Aisner J; Green M; Thomas CR; Livingston R; Johnson DH
    Cancer; 2001 Jun; 91(11):2010-5. PubMed ID: 11391579
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intensive chemotherapy with cisplatin, doxorubicin, cyclophosphamide, etoposide and granulocyte colony-stimulating factor for advanced thymoma or thymic cancer: preliminary results.
    Oshita F; Kasai T; Kurata T; Fukuda M; Yamamoto N; Ohe Y; Tamura T; Eguchi K; Shinkai T; Saijo N
    Jpn J Clin Oncol; 1995 Oct; 25(5):208-12. PubMed ID: 7474409
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term results of first-line sequential high-dose etoposide, ifosfamide, and cisplatin chemotherapy plus autologous stem cell support for patients with advanced metastatic germ cell cancer: an extended phase I/II study of the German Testicular Cancer Study Group.
    Schmoll HJ; Kollmannsberger C; Metzner B; Hartmann JT; Schleucher N; Schöffski P; Schleicher J; Rick O; Beyer J; Hossfeld D; Kanz L; Berdel WE; Andreesen R; Bokemeyer C;
    J Clin Oncol; 2003 Nov; 21(22):4083-91. PubMed ID: 14568987
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combined etoposide, ifosfamide, and cisplatin in the treatment of patients with advanced thymoma and thymic carcinoma. A French experience.
    Grassin F; Paleiron N; André M; Caliandro R; Bretel JJ; Terrier P; Margery J; Le Chevalier T; Ruffié P
    J Thorac Oncol; 2010 Jun; 5(6):893-7. PubMed ID: 20521356
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Weekly chemotherapy with cisplatin, vincristine, doxorubicin, and etoposide is an effective treatment for advanced thymic carcinoma.
    Yoh K; Goto K; Ishii G; Niho S; Ohmatsu H; Kubota K; Kakinuma R; Nagai K; Suga M; Nishiwaki Y
    Cancer; 2003 Sep; 98(5):926-31. PubMed ID: 12942558
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Octreotide alone or with prednisone in patients with advanced thymoma and thymic carcinoma: an Eastern Cooperative Oncology Group Phase II Trial.
    Loehrer PJ; Wang W; Johnson DH; Aisner SC; Ettinger DS;
    J Clin Oncol; 2004 Jan; 22(2):293-9. PubMed ID: 14722038
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cisplatin, etoposide and either bleomycin or ifosfamide in the treatment of disseminated germ cell tumors: final analysis of an intergroup trial.
    Hinton S; Catalano PJ; Einhorn LH; Nichols CR; David Crawford E; Vogelzang N; Trump D; Loehrer PJ
    Cancer; 2003 Apr; 97(8):1869-75. PubMed ID: 12673712
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Advanced stage thymomas and thymic carcinomas: results of multimodality treatments.
    Lucchi M; Ambrogi MC; Duranti L; Basolo F; Fontanini G; Angeletti CA; Mussi A
    Ann Thorac Surg; 2005 Jun; 79(6):1840-4. PubMed ID: 15919267
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prospective trial of ifosfamide, paclitaxel, and cisplatin in patients with advanced non-transitional cell carcinoma of the urothelial tract.
    Galsky MD; Iasonos A; Mironov S; Scattergood J; Donat SM; Bochner BH; Herr HW; Russo P; Boyle MG; Bajorin DF
    Urology; 2007 Feb; 69(2):255-9. PubMed ID: 17320659
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neoadjuvant etoposide, ifosfamide, and cisplatin for the treatment of olfactory neuroblastoma.
    Kim DW; Jo YH; Kim JH; Wu HG; Rhee CS; Lee CH; Kim TY; Heo DS; Bang YJ; Kim NK
    Cancer; 2004 Nov; 101(10):2257-60. PubMed ID: 15484215
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High-dose carboplatin with etoposide in patients with recurrent thymoma: the Indiana University experience.
    Hanna N; Gharpure VS; Abonour R; Cornetta K; Loehrer PJ
    Bone Marrow Transplant; 2001 Sep; 28(5):435-8. PubMed ID: 11593315
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cisplatin/etoposide chemotherapy combined with twice daily thoracic radiotherapy for limited small-cell lung cancer: a clinical phase II trial.
    Chen GY; Jiang GL; Wang LJ; Qian H; Fu XL; Yang H; Wu KL; Zhao S
    Int J Radiat Oncol Biol Phys; 2005 Jan; 61(1):70-5. PubMed ID: 15629596
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase I/II study of sequential dose-intensified ifosfamide, cisplatin, and etoposide plus paclitaxel as induction chemotherapy for poor prognosis germ cell tumors by the German Testicular Cancer Study Group.
    Hartmann JT; Gauler T; Metzner B; Gerl A; Casper J; Rick O; Horger M; Schleicher J; Derigs G; Mayer-Steinacker R; Beyer J; Kuczyk MA; Bokemeyer C;
    J Clin Oncol; 2007 Dec; 25(36):5742-7. PubMed ID: 18089869
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Comparing cisplatin plus etoposide with combination of mitomycin, ifosfamide and cisplatin in advanced non-small cell lung cancer patients].
    Cok G; Göksel T; Soyer S; Atil H; Güzelant A; Aysan T
    Tuberk Toraks; 2006; 54(2):161-7. PubMed ID: 16924573
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Alternating chemotherapy with etoposide plus cisplatin and topotecan plus paclitaxel in patients with untreated, extensive-stage small cell lung carcinoma: a phase II trial of the North Central Cancer Treatment Group.
    Jett JR; Hatfield AK; Hillman S; Bauman MD; Mailliard JA; Kugler JW; Morton RF; Marks RS; Levitt R
    Cancer; 2003 May; 97(10):2498-503. PubMed ID: 12733149
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Paclitaxel-ifosfamide-cisplatin as salvage chemotherapy in ovarian cancer patients pretreated with platinum compounds and paclitaxel.
    Polyzos A; Kosmas C; Tsavaris N; Toufexi H; Lagadas A; Gogas H; Giannakopoulos K; Kouraklis G; Griniatsos J; Felekouras E; Tsigris C; Nikiteas N; Papadopoulos O; Giannopoulos A
    Anticancer Res; 2007; 27(3B):1645-51. PubMed ID: 17595790
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase II trial of ifosfamide and cisplatin in the treatment of metastatic sarcomas: a Southwest Oncology Group study.
    Budd GT; Metch B; Weiss SA; Weick JK; Fabian C; Stephens RL; Balcerzak SP
    Cancer Chemother Pharmacol; 1993; 31 Suppl 2():S213-6. PubMed ID: 8453701
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The efficacy of a combination of etoposide, ifosfamide, and cisplatin in the treatment of patients with soft tissue sarcoma.
    Pápai Z; Bodoky G; Szántó J; Poller I; Rahóty P; Eckhardt S; Láng I; Szendroi M
    Cancer; 2000 Jul; 89(1):177-80. PubMed ID: 10897015
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A phase II study of etoposide, cisplatin, and doxorubicin chemotherapy in mixed müllerian tumors (MMT) of the uterus.
    Resnik E; Chambers SK; Carcangiu ML; Kohorn EI; Schwartz PE; Chambers JT
    Gynecol Oncol; 1995 Mar; 56(3):370-5. PubMed ID: 7705670
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Induction chemotherapy with the TIP regimen (paclitaxel/ifosfamide/cisplatin) in stage III non-small cell lung cancer.
    Pohl G; Krajnik G; Malayeri R; Müller RM; Klepetko W; Eckersberger F; Schäfer-Prokop C; Pokrajac B; Schmeikal S; Maier A; Ambrosch G; Woltsche M; Minar W; Pirker R
    Lung Cancer; 2006 Oct; 54(1):63-7. PubMed ID: 16926060
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.